Moderna eyes fall vaccine season for omicron booster after phase 2/3 success Precision hails phase 1/2 data as proof it could deliver the first approved off-the-shelf CAR-T Weight watcher: Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data Sponsored: Tech-Enabled Trials Don't Have to Mean Loss of Human Connection DBV patches up prospects with phase 3 win in infants with peanut allergies Mineralys hauls in $118M series B to advance hypertension med through phase 2 trial After late-study endpoint switch, Aldeyra hails success of phase 3 dry eye disease trial Roche's bispecific blood cancer drug Lunsumio treads on CAR-T's turf with first global approval As monkeypox cases rise, BD pairs up with Spain-based CerTest for diagnostic AHA: Nonprofit hospitals provided community benefits 9 times higher than 2019 tax exemptions Lilly, Novo Nordisk's weight loss meds could replace surgery for obesity patients: specialist Ginkgo Bioworks picks up Bitome's AI to bolster its cell engineering platform Residents of Republican counties more likely to die of COVID-19 regardless of own political beliefs, study finds Better late than never? Novavax's COVID shot gets endorsement from FDA expert panel Featured Story | By James Waldron Moderna hopes that the successful readout from a phase 2/3 trial of its omicron-targeting COVID-19 shot means the booster will be ready for people’s arms by the late summer. read more |
| |
|---|
|
Top Stories By Max Bayer Gene editing biotech Precision BioSciences is touting phase 1/2 results as proof it could bring the first approved allogeneic CAR-T drug to market. The promising, albeit early, data from the study found that 100% of evaluable patients whose cancer had relapsed had responded to the treatment. read more By James Waldron Innovent is catching up with the likes of Eli Lilly and Novo Nordisk as the Chinese pharma’s own obesity drug passes strong results in a phase 2 trial. A placebo-controlled trial of the drug, mazdutide, in 230 Chinese participants met the primary endpoint of a percentage change in baseline body weight at week 24. read more Sponsored by: Vault Health DCTs hold the promise of reducing site and patient burdens but at what cost to human connection? Vault says it doesn't have to be a compromise. read more By Nick Paul Taylor DBV Technologies has chalked up a win for its beleaguered peanut allergy patch candidate, hitting the primary endpoint in a phase 3 clinical trial in infants to send its battered share price past its prior high for 2022. read more By Max Bayer Mineralys has raised $118 million in series B funds off of the promise of its sole asset, a hypertension med that's progressing through a phase 2 trial slated to read out in a matter of months. As for future development, the company says it would likely first work on expanding the indication of the drug, MLS-101, to other cardio-metabolic disorders. read more By Nick Paul Taylor Aldeyra Therapeutics’ late-study primary endpoint switch has paid off. Weeks after disclosing the change to its dry eye disease phase 3, the biotech has reported a hit against the new primary endpoint, teeing it up to find out what the FDA makes of the data set. read more By Angus Liu After Rituxan's fall off the patent cliff, Roche is looking to new assets to replenish its blood cancer arsenal. With a first-in-class nod, the Swiss pharma is introducing a novel bispecific lymphoma drug that will first compete with powerful CAR-T therapies. read more By Conor Hale The project aims to have CerTest’s CE-marked test operate on the BD MAX automated PCR system. read more By Dave Muoio An average 13.9% of hospitals’ total expenses went toward community benefits in 2019, according to a recent report from the American Hospital Association and Ernst & Young. read more By Kevin Dunleavy Tirzepatide weight loss data presented this week by Eli Lilly are so compelling that the drug and Novo Nordisk's Wegovy could in many circumstances replace sleeve bariatric and gastric bypass surgeries—often seen as last resorts for those who are morbidly obese. That is the belief of a key opinion leading obesity specialist who was consulted by SVB Securities. read more By Andrea Park Ginkgo Bioworks has acquired certain assets from Bitome, which is developing machine learning technology to track how well individual cell lines are performing throughout the programming process. read more By Anastassia Gliadkovskaya A lack of implementation or compliance with public health measures "played a significant role" in mortality, which was likely driven by individual political beliefs. read more By Kevin Dunleavy An FDA panel of independent experts voted 21-0, with one abstention, to recommend the Novavax COVID-19 vaccine for authorization for those 18 and older. The endorsement leaves the fate of the shot in the hands of the FDA, which could sign off on it as early as this week. read more Resources Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA @Philly Cell and Gene Therapy Annual Conference 2022 June 17-18th 2022; King of Prussia, PA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 